• Pregnenolone Carbonitrile: From CYP3A to Water Balance

  2026-08-21

  Pregnenolone Carbonitrile is more than a conventional rodent PXR agonist for xenobiotic metabolism research. By combining hepatic CYP3A induction, antifibrotic activity, and newly described hypothalamic AVP regulation, this article outlines a translational framework for designing more informative PXR experiments.

• Clodronate Liposomes for Liver I/R Studies

  2026-08-21

  Clodronate Liposomes provide a practical loss-of-function tool for testing whether macrophages drive tissue injury or therapeutic response in vivo. This workflow translates a hepatic ischemia-reperfusion study into controlled depletion, matched liposome controls, and cell-state-aware readouts rather than relying on serum biomarkers alone.

• Valemetostat BA4816: Reliable EZH2 Assay Design

  2026-08-20

  This scenario-driven guide shows how Valemetostat (SKU BA4816) can be integrated into reproducible viability, proliferation, and cytotoxicity workflows. It connects biochemical potency, formulation choices, exposure design, data interpretation, and vendor selection without treating cellular responses as direct substitutes for target-level measurements.

• Everolimus (RAD001): mTOR Research Guide

  2026-08-20

  Everolimus, also called RAD001, is an orally bioavailable mTOR pathway inhibitor that forms an FKBP12 complex and suppresses downstream signaling. Its reported in vitro activity in Panc-1 and small cell lung cancer cells should be interpreted separately from clinically relevant serum exposure and from direct cell-death measurements.

• Erlotinib Workflows for EGFR Cancer Research

  2026-08-19

  Erlotinib, also called NSC 718781, provides a rapid pharmacologic way to interrogate EGFR activation, proliferation, and apoptosis in cancer models. This guide connects quantitative EGFR assays with the reference study’s SCUBE3 findings, helping researchers distinguish direct receptor blockade from broader changes in tumor-cell survival and immune signaling.

• LY2228820: A Smarter p38 MAPK Assay Strategy

  2026-08-19

  LY2228820 is a selective p38 MAP kinase inhibitor for dissecting inflammatory, stress, and tumor-associated signaling. This article develops a mechanism-aware assay strategy that distinguishes direct kinase blockade from changes in p38 dephosphorylation and downstream phenotype.

• Tacrolimus (FK506) Workflow & Troubleshooting

  2026-08-18

  Build more reproducible T-cell, cytokine, transplantation, and autoimmune assays with Tacrolimus (FK506), a potent FKBP12–calcineurin pathway inhibitor. This guide connects practical dosing and formulation choices with genetic controls, comparative immunophilin biology, and troubleshooting strategies.

• Leptin (116-130), amide, mouse: Assay Guide

  2026-08-17

  A scenario-based guide to using Leptin (116-130), amide, mouse (SKU A1024) in cell viability, proliferation, and cytotoxicity workflows. It covers peptide handling, assay compatibility, dose-response design, data interpretation, and evidence-based vendor selection.

• V5 Epitope Tag Peptide: Mechanism and Use

  2026-08-17

  The V5 Epitope Tag Peptide is a synthetic 14-amino-acid GKPIPNPLLGLDST peptide for antibody-mediated detection of recombinant proteins. Its high reported purity, solvent-specific solubility, and compatibility with Western blotting, immunoprecipitation, and imaging support controlled protein-tagging workflows.

• Tiamulin Metabolites Across Farm Animal Species

  2026-08-16

  This study mapped Tiamulin biotransformation across rats, chickens, swine, goats, and cows using in vitro and in vivo experiments coupled with UHPLC–quadrupole/time-of-flight mass spectrometry. Its main contribution is the identification of 26 metabolites, revealing species-dependent phase I pathways and refining candidate marker residues for residue monitoring in pigs and chickens.

• PGF2α/PTGFR Control of Endometrial Breakdown

  2026-08-15

  This 2024 mouse menstrual-like model study identifies PGF2α/PTGFR as a HIF-1α-regulated pathway connecting endometrial shedding with vascular remodeling. Pharmacologic inhibition with AL-8810 reduced tissue breakdown, VEGF-A expression, and vascular permeability, providing a receptor-level framework for studying prostaglandin F2α signaling in menstruation.

• Ginsenoside Rg1: Neuroimmune Protection After Anesthesia

  2026-08-15

  The reference study shows that Ginsenoside Rg1 counteracts prolonged isoflurane anesthesia-associated behavioral, synaptic, inflammatory, and intestinal barrier abnormalities in mice. Its key mechanistic contribution is evidence that regulatory T cells are required for restoring gut–immune–brain axis function, although translation beyond this controlled preclinical model remains uncertain.

• MTT Assays for Hemodynamics-Informed Nanomedicine

  2026-08-14

  MTT provides a practical metabolic activity measurement for evaluating how thrombus-targeting nanomedicines affect cultured cells. This guide connects MTT assay design with arterial-versus-venous hemodynamics while clarifying what the readout can—and cannot—prove.

• Cy3 TSA Fluorescence System Kit: Practical Guide

  2026-08-14

  Learn how Cy3 TSA Fluorescence System Kit, SKU K1051, can strengthen fixed-cell and tissue imaging when conventional fluorescence is insufficient. This scenario-based guide covers assay compatibility, protocol controls, quantitative interpretation, and practical vendor-selection criteria for reliable fluorescence microscopy detection.

• Calpeptin and EV Release in Triple-Negative Breast Cancer

  2026-08-13

  McNamee et al. systematically compared several pharmacological strategies for suppressing extracellular vesicle release from triple-negative breast cancer cells. Their results indicate that multiple EV subpopulations contribute to the transfer of aggressive traits, and that substantial inhibition of total EV release may be necessary to meaningfully reduce effects on recipient-cell migration.

464 records 8/31 page Previous Next First page 上5页 678910 下5页 Last page